Diagnostic criteria from ATP III, WHO and IDF vary enough that different segments of populations are identified as having MS .

Emphasizes the need to treat individually all components of the syndrome.

It is still important to recognize that clustering of CVD risk factor does occur and to be astute in looking for and addressing all the factors.

As more research is done the underlying common biochemical denominators are being identified and medications are being developed that address the root causes of the various components of the syndrome.